<DOC>
	<DOC>NCT01435317</DOC>
	<brief_summary>Confirmation of efficacy and safety of acoustic CR®-neuromodulation for the treatment of chronic tinnitus patients using the CE marked ANM T30 CR®-system in a real life outpatient setting. - Identification of early indicators for therapy success - Comparison of different patient groups regarding: tinnitus severity, tinnitus duration, level of hearing loss, stimulation patterns, unilateral monotonal vs. all other complex forms - Representative set of safety data in a broad patient spectrum - Measurement of tinnitus burden (TBF-12 Questionnaire) - Generation of longterm compliance data</brief_summary>
	<brief_title>Acoustic Coordinated Reset (CR®) Neuromodulation for the Treatment of Chronic Tonal Tinnitus ("RESET Real Life")</brief_title>
	<detailed_description />
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Main symptomatic subjective tonal chronical (&gt; 3 months) tinnitus &lt;60dB hearing loss men and women ≥18 years old Main serious neurologic psychiatric or internistic disease objective tinnitus Morbus Menière craniomandibular triggered tinnitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Acoustic CR®-neuromodulation</keyword>
	<keyword>ANM T30 CR®-System</keyword>
</DOC>